CN107207513B - 用于治疗疾病的稠合双环化合物 - Google Patents

用于治疗疾病的稠合双环化合物 Download PDF

Info

Publication number
CN107207513B
CN107207513B CN201580073351.8A CN201580073351A CN107207513B CN 107207513 B CN107207513 B CN 107207513B CN 201580073351 A CN201580073351 A CN 201580073351A CN 107207513 B CN107207513 B CN 107207513B
Authority
CN
China
Prior art keywords
optionally substituted
formula
compound
another embodiment
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580073351.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107207513A (zh
Inventor
本杰明·安东尼·普拉特
R·莫汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akarna Therapeutics Ltd
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Priority to CN202010634386.7A priority Critical patent/CN111662297A/zh
Publication of CN107207513A publication Critical patent/CN107207513A/zh
Application granted granted Critical
Publication of CN107207513B publication Critical patent/CN107207513B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580073351.8A 2014-11-21 2015-11-20 用于治疗疾病的稠合双环化合物 Expired - Fee Related CN107207513B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010634386.7A CN111662297A (zh) 2014-11-21 2015-11-20 用于治疗疾病的稠合双环化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083031P 2014-11-21 2014-11-21
US62/083,031 2014-11-21
PCT/US2015/062017 WO2016081918A1 (en) 2014-11-21 2015-11-20 Fused bicyclic compounds for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010634386.7A Division CN111662297A (zh) 2014-11-21 2015-11-20 用于治疗疾病的稠合双环化合物

Publications (2)

Publication Number Publication Date
CN107207513A CN107207513A (zh) 2017-09-26
CN107207513B true CN107207513B (zh) 2020-07-28

Family

ID=56014622

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580073351.8A Expired - Fee Related CN107207513B (zh) 2014-11-21 2015-11-20 用于治疗疾病的稠合双环化合物
CN202010634386.7A Pending CN111662297A (zh) 2014-11-21 2015-11-20 用于治疗疾病的稠合双环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010634386.7A Pending CN111662297A (zh) 2014-11-21 2015-11-20 用于治疗疾病的稠合双环化合物

Country Status (17)

Country Link
US (5) US10233187B2 (enExample)
EP (1) EP3221321B1 (enExample)
JP (3) JP7224102B2 (enExample)
KR (1) KR20170117020A (enExample)
CN (2) CN107207513B (enExample)
AU (2) AU2015349687B2 (enExample)
CA (1) CA2968434A1 (enExample)
CL (1) CL2017001289A1 (enExample)
CO (1) CO2017005784A2 (enExample)
ES (1) ES2911293T3 (enExample)
IL (1) IL252309B (enExample)
MX (1) MX370480B (enExample)
MY (1) MY192927A (enExample)
RU (1) RU2706007C2 (enExample)
SA (1) SA517381566B1 (enExample)
SG (2) SG11201703953WA (enExample)
WO (1) WO2016081918A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
LT3177612T (lt) 2014-08-04 2022-06-10 Nuevolution A/S Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
SG10201908881PA (en) * 2015-03-26 2019-11-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
KR20190040936A (ko) * 2016-05-25 2019-04-19 아카나 테라퓨틱스, 엘티디. 파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
EP4424364B1 (en) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Combinations for use in the treatment of cirrhosis and liver fibrosis
TW201910332A (zh) * 2017-06-02 2019-03-16 英商艾卡那治療有限公司 稠合的雙環化合物
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
EP4003350A1 (en) 2019-07-23 2022-06-01 Novartis AG Treatment comprising fxr agonists
CA3142905A1 (en) 2019-07-23 2021-01-28 Novartis Ag Combination treatment of liver diseases using fxr agonists
US20220340668A1 (en) 2019-09-03 2022-10-27 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
JP2022550312A (ja) 2019-09-30 2022-12-01 ノバルティス アーゲー Ｆｘｒアゴニストの使用を含む処置
JP2023507364A (ja) 2019-12-20 2023-02-22 ノバルティス アーゲー インテグリン阻害剤を使用する肝疾患の治療の組み合わせ
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
TW202227405A (zh) * 2020-08-24 2022-07-16 以色列商安道麥馬克西姆有限公司 用於製備經取代的吡唑之方法
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852748A (zh) * 2003-07-23 2006-10-25 埃克塞里艾克西斯公司 用作药物的氮杂䓬衍生物
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
MXPA06003150A (es) 2003-09-17 2006-08-31 Johnson & Johnson Compuestos heterociclicos fusionados.
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
WO2010036362A1 (en) 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
US8252826B2 (en) 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
JP2019520335A (ja) * 2016-05-25 2019-07-18 アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． 疾患治療用の縮合二環式化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852748A (zh) * 2003-07-23 2006-10-25 埃克塞里艾克西斯公司 用作药物的氮杂䓬衍生物
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists;Maura Marinozzi，等;《Bioorganic & Medicinal Chemistry》;20120420;第20卷;第3429-3445页 *

Also Published As

Publication number Publication date
US10233187B2 (en) 2019-03-19
US20190308977A1 (en) 2019-10-10
IL252309A0 (en) 2017-07-31
CO2017005784A2 (es) 2017-10-31
CN111662297A (zh) 2020-09-15
CL2017001289A1 (es) 2018-03-02
IL252309B (en) 2021-01-31
EP3221321A4 (en) 2018-04-25
JP7224102B2 (ja) 2023-02-17
AU2015349687B2 (en) 2020-07-09
RU2017121588A3 (enExample) 2019-05-21
US20230183247A1 (en) 2023-06-15
AU2020250270A1 (en) 2020-11-05
SG11201703953WA (en) 2017-06-29
US20210147426A1 (en) 2021-05-20
JP2023011731A (ja) 2023-01-24
CA2968434A1 (en) 2016-05-26
KR20170117020A (ko) 2017-10-20
JP2021011482A (ja) 2021-02-04
SG10202010386PA (en) 2020-11-27
MX2017006694A (es) 2018-03-16
SA517381566B1 (ar) 2021-05-16
EP3221321A1 (en) 2017-09-27
WO2016081918A1 (en) 2016-05-26
EP3221321B1 (en) 2021-12-15
ES2911293T3 (es) 2022-05-18
RU2017121588A (ru) 2018-12-24
JP2017535614A (ja) 2017-11-30
US20250171446A1 (en) 2025-05-29
MX370480B (es) 2019-12-16
AU2020250270B2 (en) 2022-08-25
CN107207513A (zh) 2017-09-26
MY192927A (en) 2022-09-15
BR112017010627A2 (pt) 2018-02-14
RU2706007C2 (ru) 2019-11-13
HK1244802A1 (zh) 2018-08-17
US20170355699A1 (en) 2017-12-14
AU2015349687A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CN107207513B (zh) 用于治疗疾病的稠合双环化合物
JP7089566B2 (ja) 疾患の処置のための縮合二環式化合物
US20200079782A1 (en) Fused bicyclic compounds for the treatment of disease
EP3463372A1 (en) Fused bicyclic compounds for the treatment of disease
HK1245795B (en) Fused bicyclic compounds for the treatment of disease
BR112017010627B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos
HK1244802B (en) Fused bicyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Buckinghamshire

Applicant after: AKARNA THERAPEUTICS, LTD.

Applicant after: Benjamin Anthony Platt

Address before: London, England

Applicant before: AKARNA THERAPEUTICS, LTD.

Applicant before: Benjamin Anthony Platt

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200728